Skip to main content
Equibles
NGNE logo

NGNE · Neurogene Inc. · Investor Relations

Track NGNE — free

Use NGNE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NGNE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$27.58 +0.91 (+3.41%)
Russell 2000 member Rebalance outlook locked
Market Cap
$533.70M
Shares
20.01M
Volume · Nov 4 208.56K Avg daily vol (3M) 291.93K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2026-11-10 15:30 UTC Guggenheim 3rd Annual Healthcare Innovation Conference Conference
2026-11-11 15:40 UTC Stifel 2026 Healthcare Conference Conference

Recent news

Date Headline
2026-08-11 Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
2026-06-29 Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
2026-06-08 Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
2026-05-12 Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
2026-04-20 Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
2026-03-24 Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
2026-02-26 Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
2026-01-12 Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
2025-11-13 Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
2025-11-12 Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
2025-11-06 Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome

Past events

Date Event Type
2026-09-15 H.C. Wainwright 28th Annual Global Investment Conference Conference

Source: https://ir.neurogene.com/

Key facts CIK 1404644 CUSIP 64135M105 13F (30d) 23 filings 23 filers Visit website Investor relations